BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases
—Company also expanding its discovery platform in complement-mediated diseases, including potent, selective, oral molecules targeting C2—
RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that initial data from ongoing phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trials in healthy volunteers show rapid, sustained and >97 percent suppression of the alternative pathway (AP) of the complement system 24 hours following a single 110 mg dose. BCX10013 has been safe and generally well-tolerated at all doses studied to date. These data support the development of BCX10013 as a potential best-in-class, once-daily, oral Factor D inhibitor for multiple complement-mediated diseases.
Related news for (BCRX)
- Breaking News: MoBot’s Latest Update as of 05/05/25 03:00 PM
- Today’s Top Performers: MoBot’s Market Review 05/05/25 02:00 PM
- BioCryst Pharmaceuticals Soars with Stellar Q1 2025 Results, Raises ORLADEYO Guidance, and Achieves Profitability Ahead of Schedule
- BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update
- BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting